次世代補体治療の世界市場：洞察、競合情勢、市場予測：2030年

世界の次世代補体治療の市場規模は、2024年から2030年までの予測期間中に15.39%のCAGRで拡大すると予測されています。次世代補体治療市場は、世界の心血管疾患、遺伝性疾患、感染症、神経疾患の有病率の増加により、楽観的な市場成長を観察しています。さらに、世界の高齢者人口の増加と次世代補体治療製品の進歩の高まりも、予測期間（2024年～2030年）中の次世代補体治療市場の収益成長につながると期待されています。

次世代補体治療市場の成長の主な要因の1つは、世界の高齢者人口の増加です。2022年10月に発表された世界保健機関（WHO）のデータによると、2015年から2050年の間に60歳以上の高齢者の数は12～22%から倍増し、2050年には21億人に達すると推定されています。さらに、2030年には世界の6人に1人が60歳以上の高齢者となります。

また、上記の情報源によれば、80歳以上の人口は2020年から2050年の間に3倍に増え、4億2,600万人に達すると予想されています。年齢が上がるにつれて、喘息、COPD、心臓発作、冠動脈疾患、アルツハイマー病などの感染症、神経疾患、呼吸器疾患、心血管疾患にかかる可能性も高まります。高齢者人口は、肺活量の減少、免疫力の低下、骨量・筋肉量の減少、身体活動能力の低下など様々な要因のために、病気に感染するリスクが最大となります。

このように、加齢に伴う身体の変化により、高齢者人口の大幅な増加は、様々な病気に罹患する人口の増加に直結します。したがって、より多くの治療薬を必要とする高齢者人口の増加は、予測期間中に次世代補体治療の市場需要に拍車をかけるとみられています。

当レポートでは、世界の次世代補体治療市場について調査し、市場の概要とともに、分子タイプ別、投与経路別、治療タイプ別、用途別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 次世代補体治療市場レポートのイントロダクション

第2章 次世代補体治療市場のエグゼクティブサマリー

第3章 規制分析

第4章 次世代補体治療市場の主な要因分析

• 次世代補体治療市場の促進要因
• 次世代補体治療市場の抑制要因と課題
• 次世代補体治療市場の機会

第5章 次世代補体治療市場におけるポーターのファイブフォース分析

第6章 次世代補体治療市場に対するCOVID-19の影響分析

第7章 次世代補体治療市場の概要

• 分子タイプ別
• 投与経路別
• 治療タイプ別
• 用途別
• 地域別

第8章 次世代補体治療市場の企業と製品プロファイル

• Roche
• Amgen
• CSL Bearings
• Innovent Biologics
• Novartis
• Regeneron
• Sanofi
• Takeda
• UCB

第9章 KOL の見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: COVID-19 Impact Analysis on Next Generation Complement Therapeutics Market
• Table 3: Next Generation Complement Therapeutics Market Analysis in Global (2021-2030)
• Table 4: Next Generation Complement Therapeutics Market Analysis in Global by Molecule Type (2021-2030)
• Table 5: Next Generation Complement Therapeutics Market Analysis in Global by Route of Administration (2021-2030)
• Table 6: Next Generation Complement Therapeutics Market Analysis in Global by Therapy Type (2021-2030)
• Table 7: Next Generation Complement Therapeutics Market Analysis in Global by Application (2021-2030)
• Table 8: Next Generation Complement Therapeutics Market Analysis in Global by Geography (2021-2030)
• Table 9: Next Generation Complement Therapeutics Market Analysis in North America (2021-2030)
• Table 10: Next Generation Complement Therapeutics Market Analysis in North America by Country (2021-2030)
• Table 11: Next Generation Complement Therapeutics Market Analysis in the US (2021-2030)
• Table 12: Next Generation Complement Therapeutics Market Analysis in Canada (2021-2030)
• Table 13: Next Generation Complement Therapeutics Market Analysis in Mexico (2021-2030)
• Table 14: Next Generation Complement Therapeutics Market Analysis in Europe (2021-2030)
• Table 15: Next Generation Complement Therapeutics Market Analysis in Europe by Country (2021-2030)
• Table 16: Next Generation Complement Therapeutics Market Analysis in France (2021-2030)
• Table 17: Next Generation Complement Therapeutics Market Analysis in Germany (2021-2030)
• Table 18: Next Generation Complement Therapeutics Market Analysis in the UK (2021-2030)
• Table 19: Next Generation Complement Therapeutics Market Analysis in Italy (2021-2030)
• Table 20: Next Generation Complement Therapeutics Market Analysis in Spain (2021-2030)
• Table 21: Next Generation Complement Therapeutics Market Analysis in the Rest of Europe (2021-2030)
• Table 22: Next Generation Complement Therapeutics Market Analysis in Asia-Pacific (2021-2030)
• Table 23: Next Generation Complement Therapeutics Market Analysis in Asia-Pacific by Country (2021-2030)
• Table 24: Next Generation Complement Therapeutics Market Analysis in China (2021-2030)
• Table 25: Next Generation Complement Therapeutics Market Analysis in Japan (2021-2030)
• Table 26: Next Generation Complement Therapeutics Market Analysis in India (2021-2030)
• Table 27: Next Generation Complement Therapeutics Market Analysis in Australia (2021-2030)
• Table 28: Next Generation Complement Therapeutics Market Analysis in South Korea (2021-2030)
• Table 29: Next Generation Complement Therapeutics Market Analysis in the Rest of Asia-Pacific (2021-2030)
• Table 30: Next Generation Complement Therapeutics Market Analysis in the Rest of the World (2021-2030)
• Table 31: Next Generation Complement Therapeutics Market Analysis in the Rest of the World by Region (2021-2030)
• Table 32: Next Generation Complement Therapeutics Market Analysis in the Middle East (2021-2030)
• Table 33: Next Generation Complement Therapeutics Market Analysis in Africa (2021-2030)
• Table 34: Next Generation Complement Therapeutics Market Analysis in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: COVID-19 Impact Analysis on Next Generation Complement Therapeutics Market
• Figure 3: Next Generation Complement Therapeutics Market Analysis in Global (2021-2030)
• Figure 4: Next Generation Complement Therapeutics Market Analysis in Global by Molecule Type (2021-2030)
• Figure 5: Next Generation Complement Therapeutics Market Analysis in Global by Route of Administration (2021-2030)
• Figure 6: Next Generation Complement Therapeutics Market Analysis in Global by Therapy Type (2021-2030)
• Figure 7: Next Generation Complement Therapeutics Market Analysis in Global by Application (2021-2030)
• Figure 8: Next Generation Complement Therapeutics Market Analysis in Global by Geography (2021-2030)
• Figure 9: Next Generation Complement Therapeutics Market Analysis in North America (2021-2030)
• Figure 10: Next Generation Complement Therapeutics Market Analysis in North America by Country (2021-2030)
• Figure 11: Next Generation Complement Therapeutics Market Analysis in the US (2021-2030)
• Figure 12: Next Generation Complement Therapeutics Market Analysis in Canada (2021-2030)
• Figure 13: Next Generation Complement Therapeutics Market Analysis in Mexico (2021-2030)
• Figure 14: Next Generation Complement Therapeutics Market Analysis in Europe (2021-2030)
• Figure 15: Next Generation Complement Therapeutics Market Analysis in Europe by Country (2021-2030)
• Figure 16: Next Generation Complement Therapeutics Market Analysis in France (2021-2030)
• Figure 17: Next Generation Complement Therapeutics Market Analysis in Germany (2021-2030)
• Figure 18: Next Generation Complement Therapeutics Market Analysis in the UK (2021-2030)
• Figure 19: Next Generation Complement Therapeutics Market Analysis in Italy (2021-2030)
• Figure 20: Next Generation Complement Therapeutics Market Analysis in Spain (2021-2030)
• Figure 21: Next Generation Complement Therapeutics Market Analysis in the Rest of Europe (2021-2030)
• Figure 22: Next Generation Complement Therapeutics Market Analysis in Asia-Pacific (2021-2030)
• Figure 23: Next Generation Complement Therapeutics Market Analysis in Asia-Pacific by Country (2021-2030)
• Figure 24: Next Generation Complement Therapeutics Market Analysis in China (2021-2030)
• Figure 25: Next Generation Complement Therapeutics Market Analysis in Japan (2021-2030)
• Figure 26: Next Generation Complement Therapeutics Market Analysis in India (2021-2030)
• Figure 27: Next Generation Complement Therapeutics Market Analysis in Australia (2021-2030)
• Figure 28: Next Generation Complement Therapeutics Market Analysis in South Korea (2021-2030)
• Figure 29: Next Generation Complement Therapeutics Market Analysis in the Rest of Asia-Pacific (2021-2030)
• Figure 30: Next Generation Complement Therapeutics Market Analysis in the Rest of the World (2021-2030)
• Figure 31: Next Generation Complement Therapeutics Market Analysis in the Rest of the World by Region (2021-2030)
• Figure 32: Next Generation Complement Therapeutics Market Analysis in the Middle East (2021-2030)
• Figure 33: Next Generation Complement Therapeutics Market Analysis in Africa (2021-2030)
• Figure 34: Next Generation Complement Therapeutics Market Analysis in South America (2021-2030)
• Figure 35: Market Drivers
• Figure 36: Market Barriers
• Figure 37: Market Opportunities
• Figure 38: PORTER's Five Force Analysis

Next Generation Complement Therapeutics Market By Molecule Type (Biologics And Small Molecules), By Route Of Administration (Intravenous, Oral, And Subcutaneous), By Therapy Type (Monotherapy And Combination Therapy), By Application (Cardiovascular, Genetic, Hematological, Infectious, Neurological And Others), and by geography is expected to advance at a respectable CAGR forecast till 2030 owing to the rising prevalence of cardiovascular, genetic, infectious and other diseases, the growing geriatric population, and the increasing advancements in the next generation complement therapeutics product arena across the globe.

The global Next Generation Complement Therapeutics Market is estimated to grow at a CAGR of 15.39% during the forecast period from 2024 to 2030. The Next Generation Complement Therapeutics market is observing an optimistic market growth due to an increase in the prevalence of cardiovascular, genetic, infectious, and neurological disorders globally, further, the growing geriatric population and the rising advancements in the Next Generation Complement Therapeutics products across the globe is also expected to result in appreciable revenue growth in the Next Generation Complement Therapeutics market during the forecast period (2024-2030).

Next Generation Complement Therapeutics Market Dynamics:

One of the main factors for the growth of the Next Generation Complement Therapeutics market is the increasing geriatric population people globally. As per the World Health Organization (WHO) data published in October 2022, it was estimated that between the years 2015-2050 the number of individuals aged 60 years and more will be doubled from 12-22% and will reach 2.1 billion by 2050. Additionally, by the year 2030, one out of every six individuals in the world will be aged 60 years or beyond.

Also, according to the abovementioned source, the number of individuals aged 80 years or more is expected to get tripled between the years 2020 and 2050 to reach 426 million population. As age increases chances of suffering from infectious, neurological, respiratory, and cardiovascular diseases such as asthma, COPD, heart attacks, coronary artery disease, Alzheimer's disease, and others also increase. The geriatric population is at the maximum risk of getting infected by diseases due to various factors such as decreased lung capacity, weaker immune system, reduced bone & muscle mass, and lowered ability for physical activity, due to which the heart pumps less blood and delivering less oxygen to the body.

Thus, due to such bodily changes with age, the significant increase in the old age population can be directly linked to an increase in the population suffering from various diseases. Therefore, the rising geriatric population requiring more therapeutics would spur the market demand for next-generation complement therapeutics during the forecast period (2024-2030)

Along with this, the rising product developmental activities in the next generation therapeutics market is also expected to drive its market growth during the forecast period. In January 2022, Kriya Therapeutics, Inc., a fully integrated company pioneering novel technologies and therapeutics in gene therapy, announced an exclusive agreement with the Medical University of South Carolina (MUSC) Foundation for Research Development for licensing next generation complement-targeted gene therapies for the treatment of geographic atrophy and other ocular diseases.

However, certain factors such as stringent regulatory approvals and guidelines for the next- generation complement therapeutics market, the undiagnosed population living with complement deficiencies, and others may act as restraints for the Next Generation Complement Therapeutics market growth.

The Next Generation Complement Therapeutics market was positively impacted during the COVID-19 pandemic owing to the rising research and development activities, leading to product launches among the general public. The COVID-19 pandemic also led to a rising number of COVID-19 patients and increasing biologics and drug launches for the treatment of COVID-19. Moreover, the vaccine development of COVID-19 has initiated the process of economic recovery with the easing of lockdown restrictions and the return of normalcy in the economic landscape which has initiated the process of resumption of activities across the pharmaceutical and healthcare sector, thereby bringing the demand for products on track in the next generation complement therapeutics market.

Next Generation Complement Therapeutics Market Segment Analysis:

Next Generation Complement Therapeutics Market by molecule type (biologics and small molecules), route of administration (intravenous, oral, and subcutaneous), therapy type (monotherapy and combination therapy), application (cardiovascular, genetic, hematological, infectious, neurological, and others), and geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the molecule type of the Next Generation Complement Therapeutics market, the biologics segment is expected to have a significant revenue share in the year 2023. This is primarily due to the rising prevalence of COVID-19 infections and other autoimmunediseases around the world and the rising product developmental activities in the biologics sector, thus driving the overall Next Generation Complement Therapeutics market.

The COVID-19 pandemic was one of the most severe pandemics that the world faced, stressing the importance of developing advanced and next-generation pharmaceuticals, to immunize and tackle the global pandemic.

According to the WHO data (2023), as of 29 November 2022, a total of 13,042,112,489 vaccine doses had been administered to the population worldwide, which have been made possible through next-generation biologics. Moreover, biologics are also used for protection against various diseases in adolescents will further spur its market growth.

In addition, as per the National Stem Cell Foundation (2023), nearly 4% of the global population gets affected by more than 80 different types of autoimmune diseases on an average such as rheumatoid arthritis, myasthenia gravis, Crohn's disease, psoriasis, scleroderma among others.

Owing to the large patient pool requiring immunity from COVID-19 and other autoimmune diseases various vaccines have recently beenapproved as next-generation complement therapeutics in the biologics sector for their treatment, thus further expanding their market growth. For example, In November 2022, Sanofi and GSK's next-generation COVID-19 booster vaccine VIDPREVTYN® BETA got approved by the European Commission, which is the first and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe.

In a similar instance, in November 2022, argenx SE, a global immunology company announced the U.S. Food and Drug Administration (FDA) acceptance granting a Biologics License Application (BLA) for SC efgartigimod (1000mg efgartigimod-PH20) for the treatment of adult patients with generalized myasthenia gravis (gMG).

Therefore, due to such rising demand for biologics coupled with the recent regulatory approvals, the market for biologics in the Next Generation Complement therapeutics market is expected to grow significantly during the forecast period.

North America is expected to dominate the overall Next-Generation Complement Therapeutics Market:

Among all the regions, North America is expected to dominate the global Next Generation Complement Therapeutics market in the year 2023 and is expected to do the same during the forecast period from 2024-2030. This can be ascribed to the rising prevalence of cardiovascular and neurological diseases, among others, and the rising research and development activities in North America during the forecast period from 2024-2030.

According to the latest study conducted by the Centre for Disease Control and Prevention (CDC), about 697,000 people in the United States died from heart disease in 2020, and about 20.1 million adults aged 20 and older had coronary artery disease (CAD). Moreover, the US was the most affected country in the world by the COVID-19 pandemic, recording the highest number of cases and deaths during the pandemic phase.

Moreover, according to the Pan American Health Organization (2023), the age-standardized death rate from the neurological condition was highest in the US, being 47.4 deaths per 100,000 population) in 2019. The mortality rate can be controlled by treating or managing the disease by giving proper therapeutic options to people, ultimately increasing the demand for Next Generation Complement Therapeutics in the North American region.

In May 2022, the US-based biotechnology company Dianthus Tx, announced the completion of its $100 million Series A financing led by 5AM Ventures and various other partners to expand leadership and scientific teams, advance the company's lead program, DNTH103, to accelerate additional discovery pipeline programs for people living with severe and rare autoimmune diseases. DNTH103 is a potent, next-generation monoclonal antibody that selectively targets the active form of complement C1s, potentially enabling a lower dosing volume and a less frequent subcutaneous administration that is further enhanced with half-life extension technology.

Therefore, the interplay of the above-mentioned factors would provide a conducive growth environment for the North America Next Generation Complement Therapeutics market during the forecast period.

Next Generation Complement Therapeutics Market Key Players:

Some of the key market players operating in the Next Generation Complement Therapeutics Market include Roche, Amgen, CSL Bearings, Innovent Biologics, Novartis, Regeneron, Sanofi, Takeda, UCB, and others.

Recent Developmental Activities in the Next-Generation Complement Therapeutics Market:

In November 2022, Sanofi and GSK's next-generation COVID-19 booster vaccine VIDPREVTYN® BETA got approved by the European Commission, which is the first and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe.

In May 2022, the US-based biotechnology company Dianthus Tx, announced the completion of its $100 million Series A financing led by 5AM Ventures and various other partners to expand leadership and scientific teams, advance the company's lead program, DNTH103, to accelerate additional discovery pipeline programs for people living with severe and rare autoimmune diseases.

In February 2022, US FDA approved Enjaymo(TM) (sutimlimab-jome) for use in patients with cold agglutinin disease and is the only approved treatment to decrease the need for red blood cell transfusion due to hemolysis, the destruction of red blood cells, in adults with cold agglutinin disease (CAD).

Key Takeaways from the Next Generation Complement Therapeutics Market Report Study

• Market size analysis for current Next Generation Complement Therapeutics Market size (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Next Generation Complement Therapeutics market.
• Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the global Next Generation Complement Therapeutics market.
• Various opportunities available for the other competitor in the Next Generation Complement Therapeutics Market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030.
• Which are the top-performing regions and countries in the current Next Generation Complement Therapeutics Market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for Next Generation Complement Therapeutics Market growth in the coming future?

Target Audience who can be benefited from this Next Generation Complement Therapeutics Market Report Study

• Next Generation Complement Therapeutics products providers
• Research and development organizations
• Next Generation Complement Therapeutics-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in Next Generation Complement Therapeutics
• Various end users who want to know more about the Next Generation Complement Therapeutics Market and the latest innovations in the Next Generation Complement Therapeutics market.

Frequently Asked Questions for Next Generation Complement Therapeutics Market:

1. What is Next Generation Complement Therapeutics?

Next Generation Complement Therapeutics help in the inhibition of the outgrowth of pathogens thereby inhibiting complement activation, thus reducing tissue inflammation, and dampening the adaptive immune response to foreign and tissue antigens.

2. What is the global market for Next Generation Complement Therapeutics?

The global Next Generation Complement Therapeutics Market is estimated to grow at a CAGR of 15.39% during the forecast period from 2024 to 2030.

3. What are the drivers for the global Next Generation Complement Therapeutics market?

The Next Generation Complement Therapeutics market is witnessing positive growth due to an increase in the prevalence of cardiovascular, genetic, infectious, neurological, and others globally, the growing geriatric population, and the rising advancements in the Next Generation Complement Therapeutics products around the world, which is further expected to result in appreciable revenue growth of the Next Generation Complement Therapeutics market during the forecast period (2024-2030).

4. Who are the key players operating in the global Next Generation Complement Therapeutics market?

Some of the key market players operating in the Next Generation Complement Therapeutics Market include Roche, Amgen, CSL Bearings, Innovent Biologics, Novartis, Regeneron, Sanofi, Takeda, UCB, and others.

5. Which region has the highest share in the Next Generation Complement Therapeutics market?

Among all the regions, North America is estimated to amass a significant revenue share in the global Next Generation Complement Therapeutics market. This can be ascribed to the rising prevalence of cardiovascular, and neurological diseases, the COVID-19 pandemic, and the rising research and development activities in North America during the forecast period from 2024-2030.

Table of Contents

1. Next Generation Complement Therapeutics Market Report Introduction

2. Next Generation Complement Therapeutics Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment

3. Regulatory Analysis

4. Next Generation Complement Therapeutics Market Key Factors Analysis

• 4.1. Next Generation Complement Therapeutics Market Drivers
  • 4.1.1. Rising prevalence of cardiovascular, genetic, infectious, neurological, and other diseases globally.
  • 4.1.2. The growing geriatric population
  • 4.1.3. Rising developmental activities in the next-generation pharmaceuticals arena.
• 4.2. Next Generation Complement Therapeutics Market Restraints and Challenges
  • 4.2.1. Stringent regulatory approvals and guidelines
  • 4.2.2. Undiagnosed population living with complement deficiency
• 4.3. Next Generation Complement Therapeutics Market Opportunities
  • 4.3.1. Increasing focus of key players on research and development activities.

5. Next Generation Complement Therapeutics Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Next Generation Complement Therapeutics Market

7. Next Generation Complement Therapeutics Market Layout

• 7.1. By Molecule Type
  • 7.1.1. Biologics
  • 7.1.2. Small Molecules
• 7.2. By Route of Administration
  • 7.2.1. Intravenous
  • 7.2.2. Oral
  • 7.2.3. Subcutaneous
• 7.3. By Therapy Type
  • 7.3.1. Monotherapy
  • 7.3.2. Combination Therapy
• 7.4. By Application
  • 7.4.1. Cardiovascular
  • 7.4.2. Genetic
  • 7.4.3. Hematological
  • 7.4.4. Infectious
  • 7.4.5. Neurological
  • 7.4.6. Others
• 7.5. By Geography
  • 7.5.1. North America
    • 7.5.1.1. United States Next Generation Complement Therapeutics Market in USD million (2021-2030)
    • 7.5.1.2. Canada Next Generation Complement Therapeutics Market in USD million (2021-2030)
    • 7.5.1.3. Mexico Next Generation Complement Therapeutics Market in USD million (2021-2030)
  • 7.5.2. Europe
    • 7.5.2.1. France Next Generation Complement Therapeutics Market in USD million (2021-2030)
    • 7.5.2.2. Germany Next Generation Complement Therapeutics Market in USD million (2021-2030)
    • 7.5.2.3. United Kingdom Next Generation Complement Therapeutics Market in USD million (2021-2030)
    • 7.5.2.4. Italy Next Generation Complement Therapeutics Market in USD million (2021-2030)
    • 7.5.2.5. Spain Next Generation Complement Therapeutics Market in USD million (2021-2030)
    • 7.5.2.6. Rest of Europe Next Generation Complement Therapeutics Market in USD million (2021-2030)
  • 7.5.3. Asia-Pacific
    • 7.5.3.1. China Next Generation Complement Therapeutics Market in USD million (2021-2030)
    • 7.5.3.2. Japan Next Generation Complement Therapeutics Market in USD million (2021-2030)
    • 7.5.3.3. India Next Generation Complement Therapeutics Market in USD million (2021-2030)
    • 7.5.3.4. Australia Next Generation Complement Therapeutics Market in USD million (2021-2030)
    • 7.5.3.5. South Korea Next Generation Complement Therapeutics Market in USD million (2021-2030)
    • 7.5.3.6. Rest of Asia Pacific Next Generation Complement Therapeutics Market in USD million (2021-2030)
  • 7.5.4. Rest of the World (RoW)
    • 7.5.4.1. Middle East Next Generation Complement Therapeutics Market in USD million (2021-2030)
    • 7.5.4.2. Africa Next Generation Complement Therapeutics Market in USD million (2021-2030)
    • 7.5.4.3. South America Next Generation Complement Therapeutics Market in USD million (2021-2030)

8. Next Generation Complement Therapeutics Market Company and Product Profiles

• 8.1. Roche
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Amgen
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. CSL Bearings
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Innovent Biologics
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Novartis
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Regeneron
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Sanofi
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Takeda
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. UCB
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us